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Abstract
Purpose: Prior studies have reported that linear accelerator (LINAC)-basedstereotactic body radiation therapy (SBRT) plans for prostate cancer are unable toachieve comparable intraprostatic doses to high-dose-rate brachytherapy (HDR).However, the utilization of flattening-filter-free (FFF) beams provides superiordose distributions compared with flattened beams. The purpose of this study wasto test the feasibility of achieving the high intraprostatic doses observed in HDR byutilizing LINAC - based SBRT with FFF beams. Methods: We randomly selected 10patients with localized prostate cancer previously treated at our institution in2013. FFF-mode LINAC-based SBRT and simulated HDR (using virtual HDRcatheters) plans were generated for each patient. The planning target volume(PTV) V100, V125, V150 and V200 values were compared between the two plansusing the two-sided paired samples t-test. Results: Regarding the PTV coverage,the mean V100 was slightly higher for SBRT at 96.47% compared with 94.68% forHDR (p = 0.003). The V125 (61.69% versus 66.51%, p = 0.004) and V200 (15.06%versus 19.66%, p < 0.001) were slightly lower for SBRT. There were no significantdifferences in V150 between the two plans (47.59% versus 49.8%, p = 0.375).Rectal and bladder dosimetry were also comparable between the two modalities,though the rectal maximum dose was lower in the SBRT plan (99.6% versus103.66%, p = 0.006) and the dose to 15cc of bladder was lower in the HDR plan(96.34% versus 78.18%, p = 0.005). Conclusion: Utilization of FFF modeLINAC-based SBRT allows for achievable dosimetry that is very similar to high doserate brachytherapy. Further studies are warranted regarding the safety andefficacy of this modality.
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1. IntroductionLocalized prostate cancer has been treated withstandard course external beam radiation therapy and/or low-dose-rate interstitial brachytherapy for manyyears. However, with technological advances in theimaging, accuracy and more sophisticated planningsoftware, further buoyed by suggestions of a lowalpha-beta ratio for prostate cancer,1-3 newhypofractionated techniques have been emerging. Onesuch technique is high-dose-rate brachytherapy (HDR).Multiple studies have demonstrated support for this
approach with a variety of fractionation schemes.4-7 Acourse of 9.5 Gy × 4 fractions is generally accepted as themost appropriate fractionation scheme.8 At the sametime, there has been an increased proliferation ofstereotactic body radiotherapy (SBRT) to deliver highdose per fraction without the necessary invasiveness ofbrachytherapy. There have been several studiessupporting the feasibility of this approach as well.9-13 Acourse of 7 - 7.25 Gy × 5 fractions has generally beenused for this modality.
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Given that most of the clinical data supportinghypofractionation is extrapolated from HDR, onequestion that has arisen has been whether treatment bySBRT can effectively and safely deliver the samefractionation schemes as HDR. Jabbari et al. havereported their early results using the Cyberknife(Accuray Inc, Sunnyvale, CA) using the standard HDRfractionation of 9.5 Gy × 4.14 Although one typicallyseeks to achieve homogeneous dose distribution forconventional external beam radiation therapy, doseinhomogeneity within the target volume may bedesirable for HDR brachytherapy and SBRT.15 While onestudy has suggested that HDR dosimetry can beachieved via the Cyberknife,15 this has been disputed bysubsequent studies due to the inability of Cyberknife, oreven linear accelerator (LINAC) based plans to achieveas high intraprostatic doses as can be achieved viaHDR.16-17Flattening filter-free beams (FFF) are increasinglybecoming available on LINACS. Prior studies have shownincreased efficiency of FFF beams18 as well as dosimetricadvantages.19-20 Furthermore, one comparative studyhas suggested that even volumetric arc based plansusing standard beams on a Varian (Varian MedicalSystems, Inc. Palo Alto, CA) LINAC is able to achieve thesame or better quality plans compared to theCyberknife.21 In this study, we hypothesize that HDR-likedosimetry can be achieved with LINAC-based SBRT byutilizing FFF beams on a Varian Truebeam LINAC.
2. Methods and MaterialsTen randomly selected low- or intermediate-riskpatients by National Cancer Care Network guidelineswith prostate cancer who were previously treated ourinstitution during the year 2013 with definitive externalbeam radiation therapy were identified. Our seriesincluded 7 men with low risk disease and 3 men withintermediate risk disease.All patients previously underwent CT simulation fortreatment planning with an endorectal balloon
(Radiadyne, Houston, TX) inflated with 60 cc of sterilewater. The planning target volume (PTV) for all caseswas defined as the prostate as was previously contouredwith a 4 mm margin all around, excluding the posteriormargin, which was 2mm. The rectum, penile bulb andbladder were all previously contoured by the physician.The urethra was not initially contoured. It was placedcentrally for the purposes of this study for both theSBRT and HDR plans.Each patient’s identical contours were planned toreceive the prescription dose for both the external beamradiation plans as well as the high dose ratebrachytherapy plans was 950 cGy per fraction for 4fractions. The SBRT plans were created using VarianEclipse V11.02 (Varian Medical Systems Inc, Palo Alto,CA). The corresponding HDR plans were created usingOncentra Master Plan TPS v3.3 SP3 (Nucletron BV,Veenendaal, the Netherlands). Catheters were virtuallyplaced by the physician and subsequently modified aspart of the planning process in order to achieve the mostoptimized plan.The planning objectives were as follows: Urethral Dmax< 130%, rectal Dmax < 100%, D2cc < 70%, D2cc bladder< 75%. At least 90% of prescription dose coverage wasrequired. For dosimetric analysis of the PTV coverage,we calculated the V100, V125, V150, and V200representing the volume of the PTV receiving 100%,125%, 150%, and 200% of the prescription dose,respectively. Variables used for dosimetric comparisonof the organs-at-risk (OARs) included: urethral Dmax(maximum point dose to the urethra), rectal Dmax(maximum point dose to the rectum), rectal D2 cc (doseto 2 cc of the rectum), bladder D2 cc (dose to 2 cc of thebladder), and bladder D15cc (dose to 15 cc of thebladder).Statistical analysis was performed using the SPSSstatistical software version 21 (IBM, Armonk, NY).Comparison was made using the simple two-sidedpaired samples t-test with statistical significance definedas a p-value < 0.05.
Table 1: Summary of planning target volume (PTV) coverageSimulated HDR LINAC FFF SBRT p-valueMean PTV V100 in % (95% CI) 94.68 (94.36-95.00) 96.47 (95.82-97.12) 0.003Mean PTV V125 in % (95% CI) 66.51 (64.18-68.84) 61.69 (59.49-63.89) 0.004Mean PTV V150 in % (95% CI) 49.8 (46.35-53.25) 47.59 (44.10-51.08) 0.375Mean PTV V200 in % (95% CI) 19.66 (18.53-20.79) 15.06 (13.88-16.24) <0.001
Table 2: Summary of rectal dosimetrySimulated HDR LINAC FFF SBRT p-valueRectal Dmax in % (95% CI) 103.66 (101.58-105.74) 99.6 (98.65-100.55) 0.006Rectal D2cc in % (95% CI) 95.14 (92.06-98.22) 94.75 (92.34-97.16) 0.859
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Table 3: Summary of bladder and urethral dosimetrySimulated HDR LINAC FFF SBRT p-valueBladder D2cc in % (95% CI) 161.00 (152.58-169.42) 148.48 (131.43-165.53) 0.155Bladder 15cc in % (95% CI) 78.18 (74.74-81.62) 96.34 (86.80-105.88) 0.005Urethral Dmax in % 135 130 0.05
Figure 1: Representative isodose distributions of A) HDR (High-dose-rate) brachytherapy and B) flattening-filter-free SBRT(stereotactic body radiation therapy) plans.  Red = PTV, Dark Blue = 90% isodose, Yellow = 100% isodose, Light Blue =150% isodose
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3. Results
3.1. PTV coverageThe analysis of the PTV dose distribution and dosemetrics for the LINAC-based SBRT and HDR is shown inTable 1.  The V100 was slightly higher with the SBRTplan compared to the HDR plan (96.47% vs. 94.68%, p =0.003) whereas the V125 (61.69% vs. 66.51%, p =0.004) and V200 (15.06% vs. 19.66%, p < 0.001) wereslightly higher with the HDR plan. The V150 (47.59 % vs.49.80%, p = 0.375) was similar between the twotreatment modalities. Figure 1 shows a comparativeplan of the two modalities showing the dose escalationregions (volume receiving at least 100% of theprescription dose), prescription isodose boundaries(V100) and dose falloff regions (V125, V150, V75, V50).
3.2. RectumRectal dosimetry is summarized in Table 2. The rectalDmax was significantly higher in the virtual HDR plan(99.6% vs. 103.66%, p = 0.006), though this was highlydependent upon the position of the catheters in the HDRplan. The rectal D2 cc (94.75% vs. 95.14%, p = 0.859)and mean rectal doses were very similar between thevirtual HDR and HDR.  However, rectal D10 and D25were significantly higher with HDR compared to theSBRT.
3.3. BladderBladder dosimetry is listed in Table 3. As the bladderDmax for HDR is consistently higher due to proximity ofthe brachytherapy source, bladder D2 cc was used as asurrogate for the bladder max dose. Although bladderD2 cc was similar for both HDR and SBRT, it variedsignificantly in the presence of a median lobe or if morethan, one catheter was placed in close proximity to thebladder. In those cases the D2 cc was higher for the HDRplan. The bladder D15 cc (96.34% vs. 78.18%, p = 0.005)and bladder dose falloff were significantly lower for theHDR plan.
3.4. UrethraTable 3 also lists dosimetry values for the urethra.Urethral Dmax was slightly higher with the SBRT plan(135% vs. 130%, p = 0.05). As a caveat, these values forthe HDR plan correlate with the placement of the needle,suggesting a correlation between the proficiency ofcatheter placement and dosimetric quality of plan. Asthe actual urethra was not identified on the CT scan, butrather placed in the middle of the prostate, the Dmaxvalues for the urethra are more as a proof of conceptrather than actual dosimetric value.
4. DiscussionConventional gantry-based LINACs are an alternativeplatform to Cyberknife to deliver SBRT and may offerpotential advantages over Cyberknife. In addition towider availability than Cyberknife, gantry-based LINACsoffer shorter treatment delivery times and improved
dosimetry. Pawlicki et al. conducted a dosimetriccomparison between Cyberknife SBRT and LINAC-basedSBRT delivered via seven-field IMRT. The LINAC-basedplans showed improved dose homogeneity with reducedrectal and bladder Dmax.22 A similar comparativeanalysis of RapidArc volume - modulated arc therapyand Cyberknife found that RapidArc was able to achievesimilar PTV coverage with consistently lower dose to theurethra and small bowel.21 Furthermore, the averageestimated treatment delivery time was substantiallyshorter with RapidArc (39 minutes vs. 3 minutes).Given these potential advantages, LINAC-based SBRTmay be a more attractive alternative to Cyberknife toperform virtual HDR. Prior studies investigating SBRTdosimetry with the Cyberknife platform have failed toachieve the high intraprostatic dosing seen with HDR.Fuller et al. compared Cyberknife SBRT plans for 10patients with simulated HDR plans.15 They found thatalthough PTV V100 was similar (median 96.5%Cyberknife vs. 96% HDR), V125 (44% vs. 67.5%), V150(8.5% vs. 38.8%), and D90 (39.8 Gy vs. 41.3 Gy) were allsignificantly lower with Cyberknife SBRT.  Similarly,Fukuda et al. compared HDR brachytherapy plans in 6patients with corresponding simulated Cyberknife SBRTplans.16 They also found that HDR had superiorintraprostatic dose concentration, with significantlyhigher V125 (79.4% vs. 48.9%) and V150 (40.8% vs.3.1%) with the HDR plans. A comparison between actualHDR treatment plans and simulated LINAC-based SBRTplans was performed by Spratt et al.17 They found thatHDR and virtual SBRT had comparable PTV V100 (mean93.08% for SBRT vs. 93.78%) and PTV V150 (42.86% vs.40.32%), but virtual SBRT was unable to match the highintraprostatic doses of HDR (mean PTV V200 of 0% forSBRT vs. 15.18% for HDR). This is in contrast to ourstudy where with the utilization of FFF beams we areable to attain nearly equivalent high intraprostaticdosing (PTV V200 of 15.06% with SBRT vs. 19.66% withHDR).Despite the challenges in obtaining the highintraprostatic doses achieved in HDR plans, the earlyresults of studies attempting a dose of 9.5 Gy × 4 viaCyberknife have been favorable. Fuller et al. 23 reportedtheir 5 year results of the utilization of this fractionationvia Cyberknife and found that the 5 year biochemicaldisease free survival was 98% for low risk and 92% forintermediate risk, with 6% late grade 3 genitourinarytoxicity, similar to those seen in HDR studies.23Additionally, a smaller study by Pontoriero et al. alsorevealed favorable 2 year results without any reportedGrade 3 toxicities.24 While these results are promising,they are both single institution studies in highlyspecialized centers utilizing the Cyberknife. With theability of the FFF mode in a linac to even more closelymimic HDR dosimetry, it would be expected that this
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fractionation schedule has the potential to be furtherstudied and, if these results are confirmed, eventuallyoffered as a therapeutic option across multiple centers.Regarding the doses to the normal organs-at-risk, ourfindings are generally in agreement with previousanalyses but differ in some aspects. We found that thebladder D2 cc was higher with the HDR plan comparedto the SBRT plan, which is consistent with theexperiences of Fuller et al.15 and Fukuda et al.16However, Spratt et al. found the bladder D2 cc was notstatistically different with their HDR plan than with theirsimulated SBRT plan.17 Rectal dosimetry in thesepreviously mentioned studies was variable as well, withFuller et al. and Spratt et al. reporting significantlyhigher rectal Dmax with SBRT and Fukuda et al.reporting non-significantly lower rectal Dmax withSBRT. However, in our study we found that the rectalDmax was significantly lower in the SBRT arm. Thesedisparate findings may be related to the superiority inefficiency and dosimetry of FFF beams over flattenedbeams.18-19 Alternatively, these differences may beoperator dependent. For example, the bladder D2 cc andrectal Dmax are both highly dependent on HDR catheterplacement. In our study, we attempted to virtually placethe catheters in the ideally best location in order toachieve optimal HDR dosimetry results. However, theanatomic insertion of catheters may result in differentdosimetric results. Additionally, differences in PTVdefinition may also account for the discordant findingsbetween studies. As in our analysis, Fuller et al. usedidentical PTVs (2 mm uniform expansion reduced to 0mm posteriorly) for both the HDR and SBRT plans.However, Fukuda et al. used larger PTV margins fortheir HDR planning (5 mm uniform expansion exceptposteriorly, which was reduced to 2-5 mm) than theirSBRT planning (2 mm uniform expansion).  Spratt et
al.17did not explicitly describe the PTV margins used intheir study. In this study we tried to select forreasonable margins that are considered acceptable ineither the HDR or SBRT setting.There are several important limitations in our analysis.First, there were a small number of patients in thisstudy. Second, we utilized simulated HDR plans whichdo not account for changes in anatomy from interstitialcatheter placement nor do they account for inaccuraciessuch as longitudinal catheter displacement. Thesignificance of these effects on dosimetry cannot beaccurately estimated. Third, although we demonstratesimilar dosimetry between simulated HDR and FFFLINAC-based SBRT, it is unclear whether increasing theintraprostatic dose for SBRT will further improveoutcomes. Multiple randomized studies of conventionalEBRT have found improved clinical outcomes with doseescalation and retrospective series of patients treatedwith LDR brachytherapy have similarly established adose-response.25-27 However, the clinical relevance ofPTV V150 and V200 have yet to be established for either
HDR or SBRT. Finally, both SBRT and HDR planningwere based on CT simulation with an endorectal balloon.While endorectal balloons are routinely employed forSBRT, they are not standardly utilized for HDR. Theeffect of an endorectal balloon on rectal dosimetry foreither SBRT or HDR is not well-defined. However, a priorstudy using an endorectal balloon in 3D conformalradiation planning suggests that an endorectal balloonmay displace the anterior rectal wall into the high doseregions,28 which would increase the rectal Dmax forboth SBRT and HDR.
5. ConclusionWe have demonstrated the feasibility of virtual HDRusing FFF mode LINAC-based SBRT, further supportingthe early results from two series supporting thisfractionation schedule. Using FFF beams, PTV V150 wassimilar to HDR with V200 approaching that of HDRwhile respecting OAR constraints. Further clinicalstudies are needed to determine the efficacy and safetyof high intraprostatic dosing via SBRT on clinicaloutcomes.
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